154 related articles for article (PubMed ID: 10323777)
1. Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice.
Franceschini G; Calabresi L; Chiesa G; Parolini C; Sirtori CR; Canavesi M; Bernini F
Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1257-62. PubMed ID: 10323777
[TBL] [Abstract][Full Text] [Related]
2. High density lipoprotein particle size restriction in apolipoprotein A-I(Milano) transgenic mice.
Bielicki JK; Forte TM; McCall MR; Stoltzfus LJ; Chiesa G; Sirtori CR; Franceschini G; Rubin EM
J Lipid Res; 1997 Nov; 38(11):2314-21. PubMed ID: 9392429
[TBL] [Abstract][Full Text] [Related]
3. Cell cholesterol efflux to reconstituted high-density lipoproteins containing the apolipoprotein A-IMilano dimer.
Calabresi L; Canavesi M; Bernini F; Franceschini G
Biochemistry; 1999 Dec; 38(49):16307-14. PubMed ID: 10587455
[TBL] [Abstract][Full Text] [Related]
4. Role of HDL phospholipid in efflux of cell cholesterol to whole serum: studies with human apoA-I transgenic rats.
Fournier N; de la Llera Moya M; Burkey BF; Swaney JB; Paterniti J; Moatti N; Atger V; Rothblat GH
J Lipid Res; 1996 Aug; 37(8):1704-11. PubMed ID: 8864954
[TBL] [Abstract][Full Text] [Related]
5. Human apolipoproteins A-I and A-II in cell cholesterol efflux: studies with transgenic mice.
Chiesa G; Parolini C; Canavesi M; Colombo N; Sirtori CR; Fumagalli R; Franceschini G; Bernini F
Arterioscler Thromb Vasc Biol; 1998 Sep; 18(9):1417-23. PubMed ID: 9743230
[TBL] [Abstract][Full Text] [Related]
6. Evidence that apolipoprotein A-IMilano has reduced capacity, compared with wild-type apolipoprotein A-I, to recruit membrane cholesterol.
Bielicki JK; McCall MR; Stoltzfus LJ; Ravandi A; Kuksis A; Rubin EM; Forte TM
Arterioscler Thromb Vasc Biol; 1997 Sep; 17(9):1637-43. PubMed ID: 9327756
[TBL] [Abstract][Full Text] [Related]
7. Targeted replacement of mouse apolipoprotein A-I with human ApoA-I or the mutant ApoA-IMilano. Evidence of APOA-IM impaired hepatic secretion.
Parolini C; Chiesa G; Zhu Y; Forte T; Caligari S; Gianazza E; Sacco MG; Sirtori CR; Rubin EM
J Biol Chem; 2003 Feb; 278(7):4740-6. PubMed ID: 12471038
[TBL] [Abstract][Full Text] [Related]
8. A novel mutant, ApoA-I nichinan (Glu235-->0), is associated with low HDL cholesterol levels and decreased cholesterol efflux from cells.
Han H; Sasaki J; Matsunaga A; Hakamata H; Huang W; Ageta M; Taguchi T; Koga T; Kugi M; Horiuchi S; Arakawa K
Arterioscler Thromb Vasc Biol; 1999 Jun; 19(6):1447-55. PubMed ID: 10364075
[TBL] [Abstract][Full Text] [Related]
9. Cholesterol efflux potential of sera from mice expressing human cholesteryl ester transfer protein and/or human apolipoprotein AI.
Atger V; de la Llera Moya M; Bamberger M; Francone O; Cosgrove P; Tall A; Walsh A; Moatti N; Rothblat G
J Clin Invest; 1995 Dec; 96(6):2613-22. PubMed ID: 8675626
[TBL] [Abstract][Full Text] [Related]
10. A loss-of-function variant in OSBPL1A predisposes to low plasma HDL cholesterol levels and impaired cholesterol efflux capacity.
Motazacker MM; Pirhonen J; van Capelleveen JC; Weber-Boyvat M; Kuivenhoven JA; Shah S; Hovingh GK; Metso J; Li S; Ikonen E; Jauhiainen M; Dallinga-Thie GM; Olkkonen VM
Atherosclerosis; 2016 Jun; 249():140-7. PubMed ID: 27105157
[TBL] [Abstract][Full Text] [Related]
11. Decreased cellular cholesterol efflux is a common cause of familial hypoalphalipoproteinemia: role of the ABCA1 gene mutations.
Mott S; Yu L; Marcil M; Boucher B; Rondeau C; Genest J
Atherosclerosis; 2000 Oct; 152(2):457-68. PubMed ID: 10998475
[TBL] [Abstract][Full Text] [Related]
12. ApoA-IMilano phospholipid complex (ETC-216) infusion in human volunteers. Insights into the phenotypic characteristics of ApoA-IMilano carriers.
Bisgaier CL; Ackermann R; Rea T; Rodrigueza WV; Hartman D
Pharmacol Res; 2016 Sep; 111():86-99. PubMed ID: 27155060
[TBL] [Abstract][Full Text] [Related]
13. Structural determinants in ApoA-I amyloidogenic variants explain improved cholesterol metabolism despite low HDL levels.
Del Giudice R; Domingo-Espín J; Iacobucci I; Nilsson O; Monti M; Monti DM; Lagerstedt JO
Biochim Biophys Acta Mol Basis Dis; 2017 Dec; 1863(12):3038-3048. PubMed ID: 28887204
[TBL] [Abstract][Full Text] [Related]
14. Apolipoprotein A-IFIN (Leu159-->Arg) mutation affects lecithin cholesterol acyltransferase activation and subclass distribution of HDL but not cholesterol efflux from fibroblasts.
Miettinen HE; Jauhiainen M; Gylling H; Ehnholm S; Palomäki A; Miettinen TA; Kontula K
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3021-32. PubMed ID: 9409289
[TBL] [Abstract][Full Text] [Related]
15. Proteolytic degradation and impaired secretion of an apolipoprotein A-I mutant associated with dominantly inherited hypoalphalipoproteinemia.
McManus DC; Scott BR; Franklin V; Sparks DL; Marcel YL
J Biol Chem; 2001 Jun; 276(24):21292-302. PubMed ID: 11292828
[TBL] [Abstract][Full Text] [Related]
16. Effect of repeated apoA-IMilano/POPC infusion on lipids, (apo)lipoproteins, and serum cholesterol efflux capacity in cynomolgus monkeys.
Kempen HJ; Gomaraschi M; Bellibas SE; Plassmann S; Zerler B; Collins HL; Adelman SJ; Calabresi L; Wijngaard PL
J Lipid Res; 2013 Sep; 54(9):2341-53. PubMed ID: 23828780
[TBL] [Abstract][Full Text] [Related]
17. Microarray analysis identifies human apoA-I
Ganzetti GS; Parolini C
Exp Cell Res; 2023 Dec; 433(1):113826. PubMed ID: 37858836
[TBL] [Abstract][Full Text] [Related]
18. Marked high density lipoprotein deficiency due to apolipoprotein A-I Tomioka (codon 138 deletion).
Wada M; Iso T; Asztalos BF; Takama N; Nakajima T; Seta Y; Kaneko K; Taniguchi Y; Kobayashi H; Nakajima K; Schaefer EJ; Kurabayashi M
Atherosclerosis; 2009 Nov; 207(1):157-61. PubMed ID: 19473658
[TBL] [Abstract][Full Text] [Related]
19. Apolipoprotein A-I(Zavalla) (Leu159-->Pro): HDL cholesterol deficiency in a kindred associated with premature coronary artery disease.
Miller M; Aiello D; Pritchard H; Friel G; Zeller K
Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1242-7. PubMed ID: 9714130
[TBL] [Abstract][Full Text] [Related]
20. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation.
Moore RE; Navab M; Millar JS; Zimetti F; Hama S; Rothblat GH; Rader DJ
Circ Res; 2005 Oct; 97(8):763-71. PubMed ID: 16151025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
